Bio-Works Technologies Current Liabilities
The Current Liabilities of Bio-Works Technologies (BIOWKS.SL) as of Oct 10, 2026 is 21.55 M SEK. In the previous year, Current Liabilities was 10.83 M SEK — a change of 98.96% (higher).
Get this data via API
Financial Data API
Current Liabilities
21.55 MSEK
YoY
98.96%
Last updated:
The Bio-Works Technologies Current Liabilities history
3 Years
10 Years
25 Years
Max
| YEAR | Current Liabilities | YoY |
|---|---|---|
| 21.55 MSEK | +98.96% | |
| 10.83 MSEK | -53.55% | |
| 23.32 MSEK | -40.25% | |
| 39.03 MSEK | +99.60% | |
| 19.55 MSEK | +81.15% | |
| 10.79 MSEK | +11.62% | |
| 9.67 MSEK | +12.18% | |
| 8.62 MSEK | +3.32% | |
| 8.34 MSEK | +105.85% | |
| 4.05 MSEK | +76.14% | |
| 2.30 MSEK | — |
Bio-Works Technologies Stock analysis
Frequently Asked Questions about Bio-Works Technologies stock
Current Liabilities of Bio-Works Technologies is 21.55 M SEK in 2025.
Current Liabilities of Bio-Works Technologies changed from 10.83 M SEK to 21.55 M SEK, representing a 98.96% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Current Liabilities Bio-Works Technologies since 2006 – with annual values, charts, and detailed analysis.
Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.
Current Liabilities's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Bio-Works Technologies historically and in real time.
Balance Sheet — Bio-Works Technologies
All Key Metrics — Bio-Works Technologies
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth